Plant Name: Elaeagnus angustifolia
Taxonomic Information:
Plant ID: NPO3808
Plant Latin Name: Elaeagnus angustifolia
Taxonomy Genus: Elaeagnus
Taxonomy Family: Elaeagnaceae
Plant External Links:
NCBI TaxonomyDB:
36777
Plant-of-the-World-Online:
323646-1
Used in Medicines:
Country/Region:
Turkey; China; Syrian Arab Republic; Jordan; IndiaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Cancer; Febrifuge; Pectoral
Geographical Distribution:
Turkey; Afghanistan; Italy; Turkmenistan; Mongolia; France; Syrian Arab Republic; Iran; Algeria; Jordan; China; Kazakhstan; Spain; Ukraine; United States; Morocco; Russia; Bulgaria; Pakistan; Romania; Albania; Tunisia; India; Uzbekistan; Austria; Greece; Hungary; Tajikistan
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR5A; FFAR1; FFAR4; ADRA2C; | |
| ALPL; ALOX15; | |
| CDC25B; | |
| DYRK1B; DYRK2; CLK1; DYRK3; DYRK1A; HASPIN; | |
| CA2; CA12; CA7; CA4; | |
| PPARA; | |
| NR1H4; | |
| MAOA; | |
| NFKB1; | |
| SLCO1B1; | |
| LMNA; FABP3; FABP5; FABP4; NISCH; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Protein Kinase | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Q9Y463 | CHEMBL5543 |
| Protein Kinase | DYRK2 | Dual-specificity tyrosine-phosphorylation regulated kinase 2 | Q92630 | CHEMBL4376 |
| Protein Kinase | CLK1 | Dual specificty protein kinase CLK1 | P49759 | CHEMBL4224 |
| Protein Kinase | DYRK3 | Dual-specificity tyrosine-phosphorylation regulated kinase 3 | O43781 | CHEMBL4575 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | HASPIN | Serine/threonine-protein kinase haspin | Q8TF76 | CHEMBL1075163 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | NISCH | Nischarin | Q9Y2I1 | CHEMBL3923 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 7.326E-09 | 9.099E-05 | CLK1, DYRK1A, DYRK1B, DYRK2, DYRK3 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.358E-09 | 9.099E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.060E-07 | 5.024E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.520E-07 | 1.095E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.917E-07 | 1.338E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.037E-07 | 1.591E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 1.326E-06 | 2.062E-03 | ADRA2C, CYP1A1, CYP1B1, FFAR1, FFAR4, NFKB1, NR1H4, SLCO1B1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.383E-06 | 5.581E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.151E-06 | 6.488E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.151E-06 | 6.488E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.968E-06 | 6.584E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 9.052E-06 | 6.958E-03 | ALPL, CA2, CYP1A2, FABP3, FFAR4, HTR5A, NFKB1, PPARA |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 9.266E-06 | 6.958E-03 | FABP3, FABP4, FABP5 |
| MF | GO:0003824; catalytic activity | GO:0004713; protein tyrosine kinase activity | 1.121E-05 | 7.398E-03 | CLK1, DYRK1A, DYRK1B, DYRK2, DYRK3 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.279E-05 | 8.193E-03 | CLK1, DYRK1A, DYRK1B, DYRK2, DYRK3 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 1.592E-05 | 8.889E-03 | HTR5A, HTR7 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.592E-05 | 8.889E-03 | CYP1A1, CYP1A2 |
| BP | GO:0023052; signaling | GO:0032228; regulation of synaptic transmission, GABAergic | 1.983E-05 | 9.812E-03 | CA2, CA7, NISCH |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.727E-09 | 3.285E-07 | HTR6, HTR7, CYP2D6, MAOA, ALOX15, HTR2C, HTR5A, PTGS1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.877E-09 | 3.285E-07 | FABP2, FABP3, FABP4, FABP5, PPARG, PPARA, PPARD |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 4.515E-07 | 1.569E-05 | HTR6, HTR7, HTR2C, ADRB2, HTR5A, ADRA2C, ADRA2B, ADRA2A, TSHR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.283E-06 | 1.049E-04 | CYP2D6, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.984E-07 | 1.383E-05 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.604E-06 | 1.049E-04 | SLCO1B1, CA2, SLCO1B3, NR1H4, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.887E-06 | 8.025E-05 | PLA2G1B, CYP1A2, ALOX15, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.080E-05 | 1.876E-04 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 4.162E-05 | 6.428E-04 | FABP4, ADRB2, TSHR, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.783E-05 | 6.648E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 7.495E-05 | 9.471E-04 | CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 9.471E-05 | 1.097E-03 | MAOA, CYP2D6, CYP1A2, CYP3A4 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.781E-04 | 2.577E-03 | PLA2G1B, MAOA, GAA, ALOX15, CYP3A4, HSD17B10, PTGS1, AKR1B10, CYP1A2, ALDH1A1, CYP1A1, ALPL, XDH |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 3.940E-04 | 3.423E-03 | HTR6, HTR7, HTR2C, ADRB2, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 6.221E-04 | 5.086E-03 | HTR6, ADRB2, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.853E-04 | 1.840E-03 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 9.068E-04 | 7.002E-03 | CLK1, NFKB1, TLR2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.285E-03 | 9.400E-03 | PLA2G1B, ALOX15, PTGS1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.165E-04 | 1.246E-03 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; MAOA; MAPT; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| NA: NA | Edema | NA | CA2; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; MAOA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; CDC25B; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
